Advertisement
Screener

AXSOME THERAPEUTICS, INC. (AXSM) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

AXSOME THERAPEUTICS, INC. Operating Cash Flow

AXSOME THERAPEUTICS, INC. (AXSM) reported Operating Cash Flow of -$53.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-10

  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.95M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$20.70M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$18.65M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $1.05M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$93.41M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$128.41M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$145.08M.
  • AXSOME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$116.51M.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30-$32.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$53.65M
10-Q · filed 2026-08-10
-$72.31M
derived: sum of 3 quarters · filed 2026-08-10
-$71.26M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$20.70M
10-Q · filed 2026-05-04
-$39.35M
derived: sum of 2 quarters · filed 2026-05-04
-$38.31M
derived: sum of 3 quarters · filed 2026-05-04
-$70.73M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31-$18.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$17.61M
derived: sum of 2 quarters · filed 2026-02-23
-$50.03M
derived: sum of 3 quarters · filed 2026-08-10
-$93.41M
10-K · filed 2026-02-23
2025-09-30$1.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
-$31.38M
derived: sum of 2 quarters · filed 2026-08-10
-$74.75M
10-Q · filed 2025-11-03
-$100.95M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$32.42M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$75.80M
10-Q · filed 2026-08-10
-$102.00M
derived: sum of 3 quarters · filed 2026-08-10
-$120.63M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31-$43.38M
10-Q · filed 2026-05-04
-$69.58M
derived: sum of 2 quarters · filed 2026-05-04
-$88.21M
derived: sum of 3 quarters · filed 2026-05-04
-$118.32M
derived: sum of 4 quarters · filed 2026-05-04
2024-12-31-$26.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$44.83M
derived: sum of 2 quarters · filed 2026-02-23
-$74.94M
derived: sum of 3 quarters · filed 2026-02-23
-$128.41M
10-K · filed 2026-02-23
2024-09-30-$18.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
-$48.74M
derived: sum of 2 quarters · filed 2025-11-03
-$102.21M
10-Q · filed 2025-11-03
-$132.57M
derived: sum of 4 quarters · filed 2026-02-23
2024-06-30-$30.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04
-$83.58M
10-Q · filed 2025-08-04
-$113.94M
derived: sum of 3 quarters · filed 2026-02-23
-$167.49M
derived: sum of 4 quarters · filed 2026-02-23
2024-03-31-$53.47M
10-Q · filed 2025-05-05
-$83.83M
derived: sum of 2 quarters · filed 2026-02-23
-$137.38M
derived: sum of 3 quarters · filed 2026-02-23
-$192.73M
derived: sum of 4 quarters · filed 2026-02-23
2023-12-31-$30.36M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23
-$83.91M
derived: sum of 2 quarters · filed 2026-02-23
-$139.26M
derived: sum of 3 quarters · filed 2026-02-23
-$145.08M
10-K · filed 2026-02-23
2023-09-30-$53.55M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12
-$108.90M
derived: sum of 2 quarters · filed 2024-11-12
-$114.72M
10-Q · filed 2024-11-12
-$142.28M
derived: sum of 4 quarters · filed 2025-02-18
2023-06-30-$55.35M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
-$61.17M
10-Q · filed 2024-08-05
-$88.73M
derived: sum of 3 quarters · filed 2025-02-18
-$111.49M
derived: sum of 4 quarters · filed 2025-02-18
2023-03-31-$5.82M
10-Q · filed 2024-05-06
-$33.38M
derived: sum of 2 quarters · filed 2025-02-18
-$56.14M
derived: sum of 3 quarters · filed 2025-02-18
-$89.68M
derived: sum of 4 quarters · filed 2025-02-18
2022-12-31-$27.56M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
-$50.32M
derived: sum of 2 quarters · filed 2025-02-18
-$83.86M
derived: sum of 3 quarters · filed 2025-02-18
-$116.51M
10-K · filed 2025-02-18
-$116.51M
10-K · filed 2023-02-28
2022-09-30-$22.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
-$56.30M
derived: sum of 2 quarters · filed 2023-11-06
-$88.95M
10-Q · filed 2023-11-06
-$88.95M
10-Q · filed 2022-11-07
-$117.79M
derived: sum of 4 quarters · filed 2024-02-23
2022-06-30-$33.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
-$66.19M
10-Q · filed 2023-08-07
-$66.19M
10-Q · filed 2022-08-09
-$95.03M
derived: sum of 3 quarters · filed 2024-02-23
-$121.81M
derived: sum of 4 quarters · filed 2024-02-23
2022-03-31-$32.65M
10-Q · filed 2023-05-09
-$32.65M
10-Q · filed 2022-05-02
-$61.49M
derived: sum of 2 quarters · filed 2024-02-23
-$88.27M
derived: sum of 3 quarters · filed 2024-02-23
-$113.66M
derived: sum of 4 quarters · filed 2024-02-23
2021-12-31-$28.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23
-$55.62M
derived: sum of 2 quarters · filed 2024-02-23
-$81.01M
derived: sum of 3 quarters · filed 2024-02-23
-$108.23M
10-K · filed 2024-02-23
-$108.23M
10-K · filed 2022-03-01
2021-09-30-$26.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
-$52.17M
derived: sum of 2 quarters · filed 2022-11-07
-$79.39M
10-Q · filed 2022-11-07
-$99.94M
derived: sum of 4 quarters · filed 2023-02-28
2021-06-30-$25.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$52.61M
10-Q · filed 2022-08-09
-$73.16M
derived: sum of 3 quarters · filed 2023-02-28
-$88.90M
derived: sum of 4 quarters · filed 2023-02-28
2021-03-31-$27.22M
10-Q · filed 2022-05-02
-$47.77M
derived: sum of 2 quarters · filed 2023-02-28
-$63.50M
derived: sum of 3 quarters · filed 2023-02-28
-$82.40M
derived: sum of 4 quarters · filed 2023-02-28
2020-12-31-$20.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28
-$36.29M
derived: sum of 2 quarters · filed 2023-02-28
-$55.18M
derived: sum of 3 quarters · filed 2023-02-28
-$78.46M
10-K · filed 2023-02-28
2020-09-30-$15.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08
-$34.63M
derived: sum of 2 quarters · filed 2021-11-08
-$57.90M
10-Q · filed 2021-11-08
-$75.47M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$18.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$42.17M
10-Q · filed 2021-08-09
-$59.74M
derived: sum of 3 quarters · filed 2022-03-01
-$70.36M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31-$23.27M
10-Q · filed 2021-05-10
-$40.84M
derived: sum of 2 quarters · filed 2022-03-01
-$51.47M
derived: sum of 3 quarters · filed 2022-03-01
-$60.15M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31-$17.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
-$28.19M
derived: sum of 2 quarters · filed 2022-03-01
-$36.88M
derived: sum of 3 quarters · filed 2022-03-01
-$46.38M
10-K · filed 2022-03-01
2019-09-30-$10.63M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$19.31M
derived: sum of 2 quarters · filed 2020-11-05
-$28.81M
10-Q · filed 2020-11-05
-$38.60M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30-$8.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$18.18M
10-Q · filed 2020-08-10
-$27.97M
derived: sum of 3 quarters · filed 2021-03-01
-$33.89M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31-$9.50M
10-Q · filed 2020-05-11
-$19.29M
derived: sum of 2 quarters · filed 2021-03-01
-$25.21M
derived: sum of 3 quarters · filed 2021-03-01
-$32.87M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31-$9.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
-$15.71M
derived: sum of 2 quarters · filed 2021-03-01
-$23.37M
derived: sum of 3 quarters · filed 2021-03-01
-$30.05M
10-K · filed 2021-03-01
2018-09-30-$5.91M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$13.58M
derived: sum of 2 quarters · filed 2019-11-07
-$20.26M
10-Q · filed 2019-11-07
-$26.55M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30-$7.67M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$14.35M
10-Q · filed 2019-08-08
-$20.64M
derived: sum of 3 quarters · filed 2020-03-12
-$27.09M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31-$6.68M
10-Q · filed 2019-05-09
-$12.97M
derived: sum of 2 quarters · filed 2020-03-12
-$19.42M
derived: sum of 3 quarters · filed 2020-03-12
-$26.52M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31-$6.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
-$12.74M
derived: sum of 2 quarters · filed 2020-03-12
-$19.84M
derived: sum of 3 quarters · filed 2020-03-12
-$26.47M
10-K · filed 2020-03-12
2017-09-30-$6.45M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
-$13.54M
derived: sum of 2 quarters · filed 2018-11-09
-$20.18M
10-Q · filed 2018-11-09
-$27.40M
derived: sum of 4 quarters · filed 2019-03-15
2017-06-30-$7.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$13.73M
10-Q · filed 2018-08-08
-$20.95M
derived: sum of 3 quarters · filed 2019-03-15
-$25.75M
derived: sum of 4 quarters · filed 2019-03-15
2017-03-31-$6.64M
10-Q · filed 2018-05-08
-$13.85M
derived: sum of 2 quarters · filed 2019-03-15
-$18.66M
derived: sum of 3 quarters · filed 2019-03-15
-$23.97M
derived: sum of 4 quarters · filed 2019-03-15
2016-12-31-$7.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
-$12.02M
derived: sum of 2 quarters · filed 2019-03-15
-$17.33M
derived: sum of 3 quarters · filed 2019-03-15
-$21.28M
10-K · filed 2019-03-15
2016-09-30-$4.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
-$10.12M
derived: sum of 2 quarters · filed 2017-11-08
-$14.06M
10-Q · filed 2017-11-08
-$16.32M
derived: sum of 4 quarters · filed 2018-03-07
2016-06-30-$5.31M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
-$9.26M
10-Q · filed 2017-08-09
-$11.51M
derived: sum of 3 quarters · filed 2018-03-07
-$13.44M
derived: sum of 4 quarters · filed 2018-03-07
2016-03-31-$3.95M
10-Q · filed 2017-05-09
-$6.20M
derived: sum of 2 quarters · filed 2018-03-07
-$8.12M
derived: sum of 3 quarters · filed 2018-03-07
-$10.23M
derived: sum of 4 quarters · filed 2018-03-07
2015-12-31-$2.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07
-$4.17M
derived: sum of 2 quarters · filed 2018-03-07
-$6.28M
derived: sum of 3 quarters · filed 2018-03-07
-$7.44M
10-K · filed 2018-03-07
2015-09-30-$1.92M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14
-$4.03M
derived: sum of 2 quarters · filed 2016-11-14
-$5.19M
10-Q · filed 2016-11-14
2015-06-30-$2.11M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2016-08-09
-$3.27M
10-Q · filed 2016-08-09
2015-03-31-$1.16M
10-Q/A · filed 2016-08-09
2014-12-31-$4.60M
10-K · filed 2017-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Elanco Animal Health Inc (ELAN)United States$11.177B-61.80
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41